PTH and osteosarcoma: Although PTH1-34 does not increase the incidences of adult osteosarcoma as reported in a 15-years US post-marketing surveillance study (Gilsenan et al., 2021), the blunting of bone-forming efficacy and potential carcinogenic effects after iPTH for 2 years has hampered the development of osteoporosis combination therapies (Black and Rosen, 2016; Eriksen and Brown, 2016; Chen S. et al., 2020).